Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.66 |
| ▸ | ACHE | P22303 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL30240018 | 0.89 | HDAC8 (0.78) | HDAC8ACHETSHRHRH1PDE4D | |
| Sulfuric Acid SCHEMBL11856466 | 0.89 | HDAC8 (0.78) | HDAC8ACHETSHRHRH1PDE4D | |
| Sulfuric Acid SCHEMBL30071023 | 0.85 | HDAC8 (0.72) | HDAC8ACHETSHRHRH1PDE4D | |
| SCHEMBL1262771 | 0.83 | HDAC8 (0.68) | HDAC8ACHETSHRHRH1PDE4D | |
| Trifluoromethanesulfonic Acid SCHEMBL8718291 | 0.83 | HDAC8 (0.41) | HDAC8ACHEGPR3KCNH2 | |
| SCHEMBL11773830 | 0.81 | HDAC8 (0.66) | HDAC8ACHETSHRHRH1PDE4D | |
| SCHEMBL589251 | 0.81 | — | — | |
| SCHEMBL29961324 | 0.81 | — | — | |
| Fluoride Ion SCHEMBL7937290 | 0.79 | HDAC8 (0.95) | HDAC8ACHETSHRHRH1PDE4D | |
| Hydrochloric Acid SCHEMBL461720 | 0.79 | HDAC8 (0.95) | HDAC8ACHETSHRHRH1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116249904-A | Method for determining the amount of NAD metabolite from a sample and methods and uses related thereto | 赫尔辛基大学 | 2023-06-09 | — | — | CN | claimed |
| EP-1230548-B1 | METHODS FOR THE QUANTITATION OF OXIDIZED GLUTATHIONE | OXIS INT INC (US) | 2007-02-14 | — | — | EP | claimed |
| EP-1230548-A1 | METHODS FOR THE QUANTITATION OF OXIDIZED GLUTATHIONE | Oxis International, Inc. (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2001035097-A9 | METHODS FOR THE QUANTITATION OF OXIDIZED GLUTATHIONE | OXIS INT INC (US) | 2001-09-27 | — | — | WO | claimed |
| US-6235495-B1 | REDUCTION USING 1-METHYL-2-VINYLPYRIDINIUM SALT | OXIS INTERNATIONAL, INC. | 2001-05-22 | — | — | US | claimed |
| WO-2001035097-A1 | METHODS FOR THE QUANTITATION OF OXIDIZED GLUTATHIONE | OXIS INTERNATIONAL, INC. (US) | 2001-05-17 | — | — | WO | claimed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11885821-B2 | Accurate measurement of glutathione for disease diagnosis and drug metabolite screening | DEFINITEK, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| CN-116249904-A | Method for determining the amount of NAD metabolite from a sample and methods and uses related thereto | 赫尔辛基大学 | 2023-06-09 | — | — | CN | disclosed |
| US-20210318339-A1 | Accurate Measurement of Glutathione for Disease Diagnosis and Drug Metabolite Screening | DEFINITEK, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-11141456-B2 | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | STEALTH BIOTHERAPEUTICS CORP (MC) | 2021-10-12 | — | — | US | disclosed |
| US-10962556-B2 | Accurate measurement of glutathione for disease diagnosis and drug metabolite screening | DEFINITEK, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200323947-A1 | THERAPEUTIC COMPOSITIONS INCLUDING FRATAXIN, LACTOFERRIN, AND MITOCHONDRIAL ENERGY GENERATING ENZYMES, AND USES THEREOF | STEALTH BIOTHERAPEUTICS CORP (MC) | 2020-10-15 | — | — | US | disclosed |
| EP-1423518-A2 | PROCESS FOR THE DETECTION OF OXIDATIVE STRESS AND KIT FOR ITS IMPLEMENTATION | Probiox SA (BE) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003016527-A2 | PROCESS FOR THE DETECTION OF OXIDATIVE STRESS AND KIT FOR ITS IMPLEMENTATION | PROBIOX SA (BE) | 2003-02-27 | — | — | WO | disclosed |
| EP-1230548-A1 | METHODS FOR THE QUANTITATION OF OXIDIZED GLUTATHIONE | Oxis International, Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001035097-A9 | METHODS FOR THE QUANTITATION OF OXIDIZED GLUTATHIONE | OXIS INT INC (US) | 2001-09-27 | — | — | WO | disclosed |
| US-6235495-B1 | REDUCTION USING 1-METHYL-2-VINYLPYRIDINIUM SALT | OXIS INTERNATIONAL, INC. | 2001-05-22 | — | — | US | disclosed |
| US-6235495-B1 | REDUCTION USING 1-METHYL-2-VINYLPYRIDINIUM SALT | OXIS INTERNATIONAL, INC. | 2001-05-22 | — | — | US | disclosed |
| WO-2001035097-A1 | METHODS FOR THE QUANTITATION OF OXIDIZED GLUTATHIONE | OXIS INTERNATIONAL, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11141456-B2 | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | ARG2, ABAT, FH | HDAC8 3656/4885ACHE 2892/4885TSHR 2468/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | HDAC8 1492/4885ACHE 3531/4885TSHR 3820/4885 |
| US-20200323947-A1 | THERAPEUTIC COMPOSITIONS INCLUDING FRATAXIN, LACTOFERRIN, AND MITOCHONDRIAL ENERGY GENERATING ENZYMES, AND USES THEREOF | ARG2, ABAT, FH | HDAC8 3656/4885ACHE 2892/4885TSHR 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.